Archive for May 2022
Clincal Trials and Tribulations Newsletter – May 2022 Edition
Welcome to the May edition of AARDEX Group’s Clinical Trials and Tribulations Newsletter – an aggregated collective of all of the industry’s hottest news and views! Breaking News New Pivotal Data Demonstrates the Clinical Benefit of Roche’s glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma Roche today announced that new pivotal data…
Read MoreIn a world of outcome-based pricing, can you afford to neglect patient adherence?
The emergence of outcome-based contracts in clinical research has placed an additional consideration on the already thorny issue of adherence. When drug companies are paid according to the real-world effectiveness of their products, ensuring people take the medications as prescribed is essential to the all-important return on investment (ROI). Modern approaches, such as digital adherence…
Read MoreAdherence to Medication: The Missing Piece in the Pharmacogenomics Puzzle
If enacted, the US’ Right Drug Dose Now Act will place pharmacogenomics on the main stage of drug development and move us further into the personalized medicine era. By supporting the use of pharmacogenetic testing to prevent adverse events (AEs) and inform the use of therapies that are tailored to a patient’s genetic makeup, it…
Read MoreHarnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research
“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.” – Bernard Vrijens, Scientific Lead, AARDEX® Group Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive…
Read MoreThe Heart of the Matter: The Role of Medication Adherence Tools in Tackling the CVD Epidemic
Despite huge strides in how cardiovascular diseases (CVD) are treated in recent years, the conditions remain among the leading causes of morbidity and mortality worldwide. At least part of the problem is that even the most effective drugs will not work if people do not take them. Yet both in routine practice and in clinical…
Read More